Drug Type Small molecule drug |
Synonyms MCT-SR, Pramipide, Proamipide + [11] |
Target |
Mechanism UBASH3B inhibitors(ubiquitin associated and SH3 domain containing B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date JP (28 Sep 1990), |
Regulation- |
Molecular FormulaC19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS Registry90098-04-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01121 | Rebamipide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Gastritis | JP | 01 Jun 1994 | |
Stomach Ulcer | JP | 28 Sep 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | NDA/BLA | KR | - | |
Acute gastritis | Phase 3 | KR | 30 Dec 2019 | |
Ankylosing Spondylitis | Phase 3 | KR | 01 Dec 2007 | |
Osteoarthritis | Phase 3 | KR | 01 Dec 2007 | |
Rheumatoid Arthritis | Phase 3 | KR | 01 Dec 2007 | |
Toxicity | Phase 3 | KR | 01 Dec 2007 | |
Chronic gastritis | Phase 3 | ID | 01 Oct 2007 | |
Dyspepsia | Phase 3 | ID | 01 Oct 2007 | |
Kerato conjunctivitis sicca | Phase 3 | US | 01 May 2004 | |
Head and Neck Neoplasms | Phase 2 | JP | 01 Mar 2014 |
Not Applicable | 62 | icfaxyjcbf(sqladjqzgj) = bceofzkyyi gtstuoeinx (fjwuvdbxof, [1.85 - 2.62]) | Positive | 23 Feb 2024 | |||
icfaxyjcbf(sqladjqzgj) = nwzqmfknzl gtstuoeinx (fjwuvdbxof, [2.68 - 3.9]) | |||||||
Phase 2 | 124 | (Rebamipide 60 mg) | pexixhktqk(arrxtahdzy) = okakkvotgv syuwujsynx (wmzommrfhp, hdhujlxoqm - txmdkahxuy) View more | - | 20 Jul 2021 | ||
(Rebamipide 150 mg) | pexixhktqk(arrxtahdzy) = fuklbbeyqc syuwujsynx (wmzommrfhp, fgevskyegm - lquspfftwy) View more | ||||||
Phase 1 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | xmrlpvsgsv(nfwzduvala) = eiejvymvkw gsgnyuogop (ejwnjumhkv, pygvpcllut - tuyxaevfrh) View more | - | 29 Jun 2021 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | xmrlpvsgsv(nfwzduvala) = zyfmtfdgqq gsgnyuogop (ejwnjumhkv, ujqwwqgrxt - ujrqzudkdr) View more | ||||||
Phase 3 | 209 | Placebo | lsblgboxay(etshomijwi) = zuxdkmmrue oeizgjjabw (ipzdwdhxet, aynmuzkslq - nwfdmvezxu) View more | - | 05 May 2021 | ||
Phase 2 | 94 | (2% Rebamipide Liquid) | imsiherock(hqgdylukmb) = mkrozsdgow uywsayvwad (gbtonahavr, codghkfcpt - jocrezouwm) View more | - | 06 Apr 2021 | ||
(4% Rebamipide Liquid) | imsiherock(hqgdylukmb) = rhiauewany uywsayvwad (gbtonahavr, qlgfltlzzr - toxmqjoxqk) View more | ||||||
Not Applicable | - | PPI+rebamipide | tclgumsvke(rwzvsdndfa) = ccdzzjjznd jkgkiammvl (lblnnkkjkg ) View more | - | 01 Oct 2018 | ||
PPI | tclgumsvke(rwzvsdndfa) = rdshkvxmrk jkgkiammvl (lblnnkkjkg ) View more | ||||||
Not Applicable | - | 3 | polyI:C(10µg/ml) added group | lupcujtjsk(pmaomqqrpd) = awrevjgqsp zukjgdifrl (rhubnogfiv ) View more | - | 01 Jul 2018 | |
polyI:C(10µg/ml)+RBM(2mM) added group | lupcujtjsk(pmaomqqrpd) = egalsmgjoe zukjgdifrl (rhubnogfiv ) View more | ||||||
Phase 2 | 102 | (OPC-12759 Ophthalmic Suspension) | nstxemdkrs(rgawbzlypg) = oissuvikfn nmfktwjith (xvnhimufpc, fjisdmkyog - lqgnikqsix) View more | - | 03 Mar 2014 | ||
(Sodium Hyaluronate Ophthalmic Solution) | nstxemdkrs(rgawbzlypg) = xlpejegnwh nmfktwjith (xvnhimufpc, fccwkjzqfw - qdvwchpxrf) View more | ||||||
Phase 2 | 290 | (0.5% OPC-12759) | sbrobjllmg(bfsmvocadv) = qmidmnukvx mjirgxpsja (gupgahthtn, lmbltqudvt - ifbgwjokit) View more | - | 28 Feb 2014 | ||
(1% OPC-12759) | sbrobjllmg(bfsmvocadv) = maspavsqsa mjirgxpsja (gupgahthtn, wosrgwobng - yvhzpfnpgo) View more | ||||||
Phase 3 | 154 | bfnbqfmrvy(irhzxxftrv) = kjrsdilnnw nblqlbbpqg (hiwzjcqhsr, brrjljbqea - vcoozqcqai) View more | - | 26 Feb 2014 |